Trials / Completed
CompletedNCT06843993
Single-Ascending Dose Study of MK-2060 in Healthy Chinese Male Adult Participants (MK-2060-009)
A Single-Ascending Dose Clinical Trial to Study the Safety, Pharmacokinetics and Pharmacodynamics of MK-2060 in Healthy Chinese Male Adult Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- Male
- Age
- 20 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The goal of the study is to learn about the safety of MK-2060 and if people tolerate it. Researchers also want to learn what happens to MK-2060 in a person's body over time.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MK-2060 | Single doses of MK-2060 administered via IV infusion on Day 1 according to randomization. |
| BIOLOGICAL | Placebo | Single doses of placebo administered via IV infusion on Day 1 according to randomization. |
Timeline
- Start date
- 2023-03-01
- Primary completion
- 2023-10-27
- Completion
- 2023-10-27
- First posted
- 2025-02-25
- Last updated
- 2025-02-25
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06843993. Inclusion in this directory is not an endorsement.